![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CYP2D7 |
Gene summary for CYP2D7 |
![]() |
Gene information | Species | Human | Gene symbol | CYP2D7 | Gene ID | 1564 |
Gene name | cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene) | |
Gene Alias | CYP2D | |
Cytomap | 22q13.2 | |
Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | A0A087X1C5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1564 | CYP2D7 | HCC1 | Human | Liver | HCC | 2.10e-06 | 1.26e+00 | 0.5336 |
1564 | CYP2D7 | HCC2 | Human | Liver | HCC | 2.78e-04 | 1.19e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
GO:00714662 | Liver | HCC | cellular response to xenobiotic stimulus | 93/7958 | 177/18723 | 4.35e-03 | 1.89e-02 | 93 |
GO:000167621 | Liver | HCC | long-chain fatty acid metabolic process | 60/7958 | 112/18723 | 1.17e-02 | 4.28e-02 | 60 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01522 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
hsa015221 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYP2D7 | SNV | Missense_Mutation | novel | c.741N>A | p.Phe247Leu | p.F247L | A0A087X1C5 | protein_coding | tolerated(0.51) | benign(0.015) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYP2D7 | SNV | Missense_Mutation | rs760158183 | c.578G>A | p.Arg193His | p.R193H | A0A087X1C5 | protein_coding | tolerated(0.25) | benign(0.031) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CYP2D7 | SNV | Missense_Mutation | rs190779911 | c.175G>A | p.Asp59Asn | p.D59N | A0A087X1C5 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CYP2D7 | SNV | Missense_Mutation | novel | c.553N>A | p.Val185Met | p.V185M | A0A087X1C5 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
CYP2D7 | SNV | Missense_Mutation | novel | c.1343N>T | p.Pro448Leu | p.P448L | A0A087X1C5 | protein_coding | deleterious(0.04) | possibly_damaging(0.556) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CYP2D7 | SNV | Missense_Mutation | rs748970618 | c.664N>A | p.Glu222Lys | p.E222K | A0A087X1C5 | protein_coding | tolerated(0.05) | benign(0.007) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CYP2D7 | SNV | Missense_Mutation | rs766724528 | c.633G>T | p.Glu211Asp | p.E211D | A0A087X1C5 | protein_coding | tolerated(0.31) | benign(0.011) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CYP2D7 | SNV | Missense_Mutation | rs775086719 | c.806G>A | p.Arg269Gln | p.R269Q | A0A087X1C5 | protein_coding | deleterious(0.01) | benign(0.259) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
CYP2D7 | SNV | Missense_Mutation | rs1135819 | c.311N>T | p.Ala104Val | p.A104V | A0A087X1C5 | protein_coding | tolerated(1) | benign(0) | TCGA-B5-A3S1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD |
CYP2D7 | SNV | Missense_Mutation | novel | c.1227N>T | p.Lys409Asn | p.K409N | A0A087X1C5 | protein_coding | deleterious(0) | possibly_damaging(0.527) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |